The half-life that changed metabolic medicine.

There is a particular kind of pharmacology paper that, on first read, sounds like an act of stubbornness. Native human GLP-1 has a half-life of about two minutes. The peptide is cleaved almost the moment it enters circulation by an enzyme called dipeptidyl peptidase-4, which trims it from the N-terminus and leaves an inactive fragment behind. To turn this molecule into a viable therapeutic, chemists at Novo Nordisk made two small changes: they swapped one amino acid at position 8 to resist that enzyme, and they hung an eighteen-carbon fatty-acid chain off a lysine at position 26.

The fatty-acid tail does something elegant. It binds reversibly to circulating albumin, the body's most abundant blood protein, and uses albumin as a chaperone. The peptide is no longer recognized as a foreign small molecule worth filtering. Its half-life climbs from two minutes to roughly 165 hours.

From that single engineering decision, an entire decade of metabolic medicine reorganized itself.

Origin

The lineage runs through three compounds. Exenatide, isolated from the saliva of the Gila monster lizard, proved that a stable GLP-1-like peptide could control glucose. Liraglutide, Novo Nordisk's first attempt at a longer-lasting analog, achieved a daily injection schedule. Semaglutide, approved by the FDA in 2017 under the trade name Ozempic and then in 2021 for chronic weight management as Wegovy, achieved once-weekly dosing. The work that earned it those approvals was led at Novo Nordisk's R&D site in Måløv, Denmark, and at clinical centers across more than thirty countries.

Mechanism

GLP-1 receptors are not confined to the pancreas. They appear on the membranes of beta cells, on hypothalamic neurons that govern hunger, on the gastric pylorus, on the heart's atria, on cortical and hippocampal neurons, and even on certain immune cells. Activation triggers cyclic AMP. The downstream consequences depend entirely on which cell received the signal.

Think of it less as a drug and more as a hormone-mimicking key that fits a lock found across many organ systems. Each lock controls a different door.

In the pancreatic beta cell, semaglutide augments glucose-stimulated insulin release. The augmentation is glucose-dependent — when blood sugar is normal, the molecule does very little, which is why hypoglycemia is rare. In the hypothalamus, the same receptor on neurons of the arcuate nucleus reduces appetite by activating proopiomelanocortin pathways. In the stomach, gastric emptying slows by 30 to 70 percent, which contributes to the sense of fullness.

The cardiovascular receptors are where the surprises started.

What the latest research shows

The SELECT trial, published in the New England Journal of Medicine in late 2023 and analyzed in granular detail through 2024, enrolled 17,604 adults with established cardiovascular disease and a body-mass index of 27 or higher. None had diabetes. The hypothesis was modest: would semaglutide reduce major adverse cardiovascular events in a population that had been excluded from the diabetes trials? The answer was a 20 percent relative-risk reduction in the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

A prespecified subgroup analysis published in The Lancet by Deanfield and colleagues at University College London showed that benefit extended to participants with prevalent heart failure, including those with preserved ejection fraction — a population in which almost nothing else has worked.

The kidney signal was even more striking. The FLOW trial (NEJM, May 2024), led by Vlado Perkovic at the University of New South Wales in Sydney, was stopped early after a planned interim analysis. Across 3,533 patients with type 2 diabetes and chronic kidney disease, semaglutide reduced major kidney disease events by 24 percent. Cardiovascular death dropped 29 percent. The trial's early termination was not for safety — it was because the benefit had become too clear to justify continuing the placebo arm.

The SELECT cardiovascular benefit appeared at five months — well before maximum weight loss. Whatever was protecting these hearts was not just downstream of the scale.

Hepatology has been moving quickly too. The phase 3 ESSENCE trial, with results published in 2025, demonstrated that 2.4mg semaglutide induced steatohepatitis resolution in 36 to 63 percent of MASH patients depending on fibrosis stage. Investigators at Yokohama City University and Angers University Hospital contributed pathology adjudication.

Then there is the addiction literature. A phase 2 randomized trial published in JAMA Psychiatry in early 2025, conducted at the University of North Carolina at Chapel Hill with collaborators at the Centre for Addiction and Mental Health in Toronto, gave 48 adults with alcohol use disorder either low-dose semaglutide or placebo for nine weeks. Weekly alcohol craving dropped. Drinks per drinking day dropped. A subsample with current cigarette use cut their daily cigarette count. None of these effects were predicted by the metabolic work.

Beyond the obvious

The brain effect is what most quietly redraws the map. GLP-1 receptors are densely expressed in the ventral tegmental area and the nucleus accumbens — the dopaminergic circuitry that governs reward salience. Investigators at the Hannover Medical School and at the University of Gothenburg in Sweden have proposed that GLP-1 agonism dampens the relative valence of food and substance cues without abolishing reward itself.

The Alzheimer's question is open. Two phase 3 trials, evoke and evoke+, designed by a consortium led from the Chambers-Grundy Center at the Kirk Kerkorian School of Medicine in Las Vegas, are testing oral semaglutide in early symptomatic Alzheimer's disease. Both trials read out in late 2025. The mechanistic rationale is brain insulin resistance — a feature of Alzheimer's pathology that GLP-1 receptor activation may partially correct.

A separate line of inquiry, pursued in animal models at the Karolinska Institute, has examined GLP-1 agonism in inflammatory bowel disease. The receptor is expressed on intestinal lymphocytes, and chronic activation appears to reduce TNF-alpha signaling in colitis models. Whether that translates is an open empirical question.

Often studied alongside

Recent papers have paired semaglutide with Tirzepatide and with the triple-receptor agonist Retatrutide in head-to-head and combination protocols, particularly when investigating differential effects on visceral versus subcutaneous adiposity. Adjacent research at the University of Turin has examined semaglutide in concert with AOD-9604 in animal models of metabolic dysfunction-associated steatotic liver disease, where the lipolytic and incretin pathways may be complementary rather than redundant.

Practical considerations

Reconstituted semaglutide is stable at 2–8 °C for 28 days in laboratory conditions; the lyophilized compound is stable below -20 °C for several years. The 165-hour half-life means that steady-state concentrations are not reached until roughly week four or five of weekly dosing — a fact that explains why many trials use 16-week titration schedules to reduce nausea, the most common adverse signal.

Subcutaneous administration is the standard research route. Oral semaglutide exists, formulated with the absorption enhancer SNAC, but bioavailability is roughly 1 percent and remains a less common research tool than the injectable form. All of the above is research-use-only protocol context — Precursor's compounds are not for human consumption.